Pacira BioSciences reported third-quarter 2025 revenue of $179.5 million, up 6% year over year, with Exparel delivering $139.9 million on 9% volume growth offset by vial mix and GPO discounting. Zilretta contributed $29.0 million, and iovera $6.5 million. The company returned to GAAP profitability, reporting $5.4 million in net income and $49.4 million in adjusted EBITDA. Full-year revenue guidance was trimmed to $725–$735 million, while non-GAAP gross margin guidance was raised to 80–82%, reflecting manufacturing efficiencies. Pacira also repurchased $50 million in shares, secured a new Exparel patent listed in the FDA Orange Book extending to 2044, concluded enrollment in Part A of a Phase 2 study for its OA knee gene therapy PCRX-201, and in-licensed AMT-143, a long-acting ropivacaine for postsurgical pain.
The quarter reads as a deliberate trade-off: access over price to defend share in a channel shifting toward tenders and generics. Pacira’s GPO strategy is pushing volume but pressuring net price, while upgraded margin guidance suggests the company’s scaled manufacturing network is absorbing some of the discounting. The raised gross margin outlook, despite lower revenue guidance, underscores a pivot to operational discipline as a buffer against near-term pricing headwinds.
This matters now because the non-opioid perioperative segment is entering its most competitive phase. For hospitals and ambulatory surgery centers, expanded contracting could increase availability of opioid-sparing options, but also sets a new pricing floor that payers and IDNs will drag into future negotiations. For surgeons and anesthesiologists, Exparel’s broad regional block label remains a practical differentiator. Yet, consumerization of local analgesia is accelerating, with generic liposomal bupivacaine, ZYNRELEF, and emerging long-acting local anesthetics raising the bar on both evidence and cost-effectiveness. Medical Affairs teams will be pressed to generate comparative RWE that proves not just opioid reduction but meaningful clinical endpoints that justify premium positioning in formularies that are becoming more price-driven.
Beyond price defense, Pacira is building an optionality stack. The AMT-143 license brings a long-acting ropivacaine that could be positioned as a simpler, procedure-aligned alternative in outpatient settings, potentially hedging Exparel but also risking intra-portfolio cannibalization unless differentiated by indication, setting, or delivery. In osteoarthritis, PCRX-201, with RMAT designation, signals a larger strategic ambition: migrate from perioperative analgesia into chronic musculoskeletal disease with locally administered genetic medicine. If durable symptom control translates in Phase 2 and beyond, Pacira’s commercial dialogue could shift from pharmacy-and-therapeutics committees to broader value constructs in orthopedics, including site-of-care economics and longitudinal outcomes—though the late-2026 timeline leaves Exparel and Zilretta to carry the near-term load.
The broader trend line is clear: non-opioid pain management is benefiting from policy attention and evolving reimbursement constructs, but the window to convert tailwinds into durable economics is narrowing as competitive entrants and procurement blocs reset pricing norms. What to watch next is the net price trajectory of Exparel under new GPO agreements, the practical impact of process-based patenting on substitution at the IDN level, early clinical and delivery details for AMT-143 that define its edge versus liposomal formulations and generics, and any CMS moves that further recognize non-opioid modalities. The strategic question is whether Pacira can turn scale and portfolio breadth into a defensible margin before OA gene therapy readouts change the growth narrative—or whether price erosion in perioperative analgesia outruns the company’s innovation clock.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
